scholarly journals Daylight photodynamic therapy in Scotland

2017 ◽  
Vol 62 (2) ◽  
pp. 48-53 ◽  
Author(s):  
Helen Cordey ◽  
Ronan Valentine ◽  
Andrea Lesar ◽  
Harry Moseley ◽  
Ewan Eadie ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
Treatment Options ◽  
Response To Treatment ◽  
Patient Treatment ◽  
Skin Changes ◽  
Actinic Keratoses ◽  
Home Based ◽  
Red Led ◽  
Therapy Services ◽  
Daylight Exposure

Chronic sun-induced dysplastic skin changes (actinic keratoses) are extremely common in fair-skinned people in Scotland. These changes are a major cause of morbidity and may develop into skin cancer. Actinic keratoses are often extensive and pose a therapeutic challenge as field-directed treatment is required for chronic disease management. One such treatment approach is hospital-based photodynamic therapy, which is a well-established treatment in Scotland for actinic keratoses, using a photosensitiser pro-drug and red LED light irradiation. However, photodynamic therapy using daylight as the activating light source is increasingly and effectively used in continental Europe, but had not been explored in Scotland until we initiated this in 2013. We report our experience of daylight photodynamic therapy in 64 patient-treatment courses and demonstrate that this can be an effective, well-tolerated treatment, which is liked by patients. Our most recent data show that most patients (73%) achieved clearance or at least a good response to treatment and had high levels of satisfaction with daylight photodynamic therapy. Daylight exposure measurements indicated that treatment is feasible in Scotland between April to September. Daylight photodynamic therapy is an important advancement in treatment options for Scottish patients with extensive pre-cancerous field changes and provides opportunities for home-based treatment and increased efficiency of photodynamic therapy services.

Evaluation of a cell viability assay based on cultures of CTICs to identify treatment options in third-line pancreatic cancer.

2017 ◽  
Vol 35 (4_suppl) ◽  
pp. 338-338
Author(s):  
Mark Ricigliano ◽  
William H. Isacoff ◽  
Allyson J. Ocean ◽  
Brandon Cooper ◽  
Mary Welkie ◽  
...  
Keyword(s):  
Cell Viability ◽  
Treatment Options ◽  
Standard Of Care ◽  
Response To Treatment ◽  
Patient Treatment ◽  
P Value ◽  
Line Treatment ◽  
Cell Viability Assay ◽  
Viability Assay ◽  
A Cell

338 Background: Standard of care treatment for pancreatic adenocarcinoma (PDAC) includes FOLFIRINOX or gemcitabine with nab-paclitaxel used in either the front-line or 2nd line treatment setting. There is no consensus for 3rd line treatment for this cohort of poor prognosis patients with clinical trials being the only viable option. We evaluated a cell viability assay using cultures of circulating tumor and invasive cells (CTICs) to identify effective 3rdline PDAC treatment options. Methods: CTICs were isolated from peripheral blood samples of 17 PDAC patients who previously had received one of the two standard of care regimens using an immunomagnetic separation for EPCAM epitope Ber-EP4 and cultured in enriched DMEM-F12 medium. After 14 days, seven chemotherapeutics (gemcitabine (G), oxaliplatin (O), fluorouracil (F), irinotecan (I), mitomycin C (M), cisplatin (C) and paclitaxel (P)) were added to the cultures and response to treatment was measured 48 hr. after treatment by immunofluorescence using a live-cell resazurin assay. Response to treatment was determined by a reduction of fluorescence in the treated cultures compared to control and the mean florescence (Fm) was calculated for each chemotherapeutic. A one-sample t-test was used to measure the variance between Fm control and treated samples. (p-value <0.005). Sensitivity to treatment was determined using linear regression based on Fm values and the sensitivity of each chemotherapeutic was interpolated from a standard curve (range 1.0-5.0, sensitive <2, intermediate 2-3, resistant >3). Results: m (Fm=1.6) demonstrated the most effective treatment option with marked resistance to treatment for G, I, P and O. (Fm=3.4, 3.7, 3.4 and 3.7). Intermediate response was observed for F and C (Fm=2.8 and 2.8). Patient treatment response to m will be described. Conclusions: CTICs can be routinely isolated and cultured for cell viability assays. m based regimens with C and F should be considered for 3rd line PDAC patients.

scholarly journals Influence of Serum Vitamin D Level in the Response of Actinic Keratosis to Photodynamic Therapy with Methylaminolevulinate

2020 ◽  
Vol 9 (2) ◽  
pp. 398
Author(s):  
Ricardo Moreno ◽  
Laura Nájera ◽  
Marta Mascaraque ◽  
Ángeles Juarranz ◽  
Salvador González ◽  
...  
Keyword(s):  
Vitamin D ◽  
Photodynamic Therapy ◽  
Aminolevulinic Acid ◽  
Serum Vitamin ◽  
Histochemical Staining ◽  
Response To Treatment ◽  
Vitamin D Status ◽  
Tumor Cell Death ◽  
Actinic Keratoses ◽  
Serum Vitamin D

In mouse models of squamous cell carcinoma, pre-treatment with calcitriol prior to photodynamic therapy with aminolevulinic acid (ALA) enhances tumor cell death. We have evaluated the association between vitamin D status and the response of actinic keratoses to photodynamic therapy with methylaminolevulinate. Twenty-five patients with actinic keratoses on the head received one session of photodynamic therapy with methylaminolevulinate. Biopsies were taken at baseline and six weeks after treatment. Immuno-histochemical staining was performed for VDR, P53, Ki67 and β-catenin. Basal serum 25(OH)D levels were determined. Cases with a positive histological response to treatment had significantly higher serum 25(OH)D levels (26.96 (SD 7.49) ngr/mL) than those without response (18.60 (SE 7.49) ngr/mL) (p = 0.05). Patients with a complete clinical response displayed lower basal VDR expression (35.71% (SD 19.88)) than partial responders (62.78% (SD 16.735)), (p = 0.002). Our results support a relationship between vitamin D status and the response of actinic keratoses to photodynamic therapy with methylaminolevulinate.

Sign in / Sign up

Export Citation Format

Share Document